IMPORTANCE According to the 2012 International Consensus Guidelines, the diagnostic criterion of intraductal papillary mucinous neoplasms (IPMNs) involving the main duct (MD IPMNs) or the main and branch ducts (mixed IPMNs) of the pancreatic system is a main pancreatic duct (MPD) diameter of 5.0 mm or greater on computed tomography (CT) or magnetic resonance imaging (MRI). However, surgical resection is recommended for patients with an MPD diameter of 10.0 mm or greater, which is characterized as a high-risk stigma. An MPD diameter of 5.0 to 9.0 mm is not an indication for immediate resection.
I ntraductal papillary mucinous neoplasms (IPMNs) of the pancreas are classified radiographically into the following 3 types based on the degree of involvement of the pancreatic ductal system: main duct (MD), branch duct (BD), and features of MD and BD (mixed). 1, 2 Intraductal papillary mucinous neoplasms progress to malignant disease over time. 3, 4 Those involving the MD (MD IPMNs or mixed IPMNs) are generally categorized separately because the rate of progression to malignant disease is significantly higher than that for BD IPMNs in resected cases (36%-87% vs 6%-47%). [5] [6] [7] [8] [9] The original International Consensus Guidelines for the management of IPMNs and mucinous cystic neoplasms of the pancreas in 2006 defined MD IPMN as a diameter of the main pancreatic duct (MPD) of 10.0 mm or greater on computed tomography (CT) or magnetic resonance imaging (MRI) and recommended that all MD IPMNs and mixed IPMNs should be resected if the patient is a good surgical candidate with a reasonable life expectancy. 10 In 2012, based on the accumulated evidence, the revised version of the International Consensus Guidelines (2012 Guidelines) changed the diagnostic criterion of MD IPMNs and mixed IPMNs to a smaller MPD diameter of 5.0 mm, 11 to increase the sensitivity of radiologic diagnosis. According to the 2012 Guidelines, those MD or mixed IPMNs with "high-risk stigmata," defined as biliary obstruction, an enhancing solid component within a cyst on CT or MRI, or an MPD diameter of 10.0 mm or greater on CT or MRI, should be resected. 12 An MPD diameter of 5.0 to 9.9 mm is considered a "worrisome feature" but is not an immediate indication for surgical resection. For those patients with worrisome features, endoscopic ultrasonography (EUS) is recommended. If, on EUS, (1) a definite mural nodule, (2) MD involvement (thickened walls, intraductal mucin, or mural nodules), or (3) positive cytologic findings of a fine-needle aspiration (FNA) biopsy are identified, surgical resection should be recommended. Conversely, patients without any of these high-risk features on EUS can be observed with surveillance. However, we have anecdotally observed a number of MD or mixed IPMNs harboring malignant disease with an associated MPD diameter less than 10.0 mm. As a result, the decision to observe those cases in which the MPD diameter is 5.0 to 9.9 mm without high-risk stigmata or worrisome features, or even without high-risk features on EUS, involves a degree of discomfort. Therefore, the objectives of the present study were to critically analyze the association of MPD diameter with malignant disease and determine a cutoff with the highest sensitivity and negative predictive value. Furthermore, we sought to propose a new management algorithm that incorporates this new diameter as a high-risk feature and determine whether the algorithm could identify patients with malignant IPMN who did not have other high-risk features and would have been missed under the 2012 Guidelines.
Methods

Patients
A total of 1750 patients who underwent pancreatic resection from July 1, 1996, to December 31, 2015, were identified in a prospectively maintained database. Patients were included in this study if they had a cystic lesion on preoperative CT or MRI that was suggestive of IPMN and underwent pancreatectomy with pathologic confirmation. Patients with a history of pancreatectomy were excluded. Patients who underwent pancreatectomy for another indication and had an IPMN identified incidentally in the index lesion on surgical specimen were excluded. Patients with a clinical history of chronic pancreatitis or with suspected chronic pancreatitis on radiologic examinations were also excluded. Using these criteria, 190 patients were identified with preoperative and postoperative diagnoses of IPMN. This study was approved by the institutional review board from the University of California, Los Angeles (UCLA). Informed consent regarding this study was deemed not necessary by the institutional review board.
We distinguished MD, BD, or mixed IPMNs radiologically using the 2012 Guidelines. 11 
Surgery and Pathologic Examination
In general, our indications for surgical resection for the suspected MD or mixed IPMNs were in accordance with the 2012 Guidelines. 11 Several surgically fit patients without high-risk stigmata underwent surgery because they had at least 1 episode of acute pancreatitis or were anxious about the uncertainty of the malignant risk of their cyst despite comprehensive evaluations. The type of operation, which included pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy, depended on the location and distribution of the lesion that caused concern for the presence of malignant disease on imaging examinations. A pathologic diagnosis of IPMN was made according to the current World Health Organization guidelines for IPMN. 12, 13 Lesions were classified as low-grade dysplasia, high-grade dysplasia, or invasive adenocarcinoma. Intraoperative frozensection examination of the pancreatic resection margin was performed. If high-grade dysplasia or invasive adenocarcinoma was detected at intraoperative frozen-section analysis, an additional pancreatic resection-total pancreatectomy at most-was performed until a lower pathologic grade was reached, if the patient was deemed to be fit for the extensive resection. For our analysis, IPMN with low-grade dysplasia was regarded as benign, whereas IPMN with high-grade dysplasia or invasive adenocarcinoma was regarded as malignant.
Statistical Analysis
First, to evaluate the appropriateness of the MPD diameter of 10.0 mm as a cutoff for a high-risk stigma of IPMN, we compared the surgical pathologic findings between patients with an MPD diameter less than 10.0 mm and 10.0 mm or greater. We used the χ 2 test for categorical variables and the MannWhitney test for continuous variables. Then, an appropriate cutoff value of the MPD diameter in relation to malignant disease was determined using receiver operating characteristic curve analysis. Moreover, prognostic risk analysis for malignant disease was performed using logistic regression analysis. Variables with P < .05 on univariate analysis were included in multivariate analysis. A 2-sided P < .05 was considered statistically significant. All statistical analyses were performed using SPSS Statistics (version 19.0; SPSS, Inc).
Results
Clinical Findings for All Patients
The clinical characteristics for all 103 patients who underwent resection for MD or mixed IPMN are shown in were compared between patients with an MPD diameter of 5.0 to 9.9 mm and those with an MPD diameter of 10.0 mm or greater ( Table 2) . We found a significant difference in pathologic size of the cystic lesion between these groups (2.7 [range, 0.5-5.5] cm and 3.2 [range, 0.7-10.5] cm, respectively; P = .008). However, no difference was noted in other pathologic findings associated with aggressive biological features.
Determination of a Cutoff Value of the MPD Diameter in Relation to Malignant Disease
The median MPD diameter was 11.9 (range, 5.6-53.0) mm for the patients with malignant IPMNs and 10.0 (range, 5.0-37.0) mm for those with benign IPMNs (P < .001). On logistic regression analysis, the MPD diameter, as a continuous variable, was significantly associated with malignant disease (odds ratio [OR], 1.12; 95% CI, 1.02-1.23; P = .02).
Because we found no difference in the presence of malignant disease between patients with an MPD diameter of less than 10.0 mm and 10.0 mm or greater (Table 2) , we sought to determine an appropriate cutoff for the MPD diameter to estimate the presence of malignant disease by generating a receiver operating characteristic curve (Figure 1) . The area under the receiver operating characteristic curve was 0.70 (95% CI, 0.59-0.81). The area under the curve was maximized at an MPD diameter cutoff of 7.2 mm, where the statistics to estimate malignant disease were sensitivity of 97%, specificity of 41%, positive predictive value (PPV) of 73%, negative predictive value (NPV) of 89%, and accuracy of 76%.
Risk Analysis for Malignant Disease
Preoperative variables that were obtained for more than half of the patients were evaluated for the risk for malignant dis- The area under the curve (AUC) was maximized at an MPD diameter cutoff of 7.2 mm. 
Application of the Management Algorithm for Our Patient Population
We modified the 2012 Guidelines by incorporating our results and established a new management algorithm using the new MPD diameter cutoff of 7.2 mm on CT and/or MRI ( Figure 2 ). In this UCLA algorithm, those patients with highrisk stigmata (ie, the presence of biliary obstruction, an enhancing solid component within a cyst on CT and/or MRI, or an MPD diameter of ≥7.2 mm on CT and/or MRI) are recommended to undergo surgery. Those patients with an MPD diameter less than 7.2 mm are recommended to undergo EUS. Finally, surgery is also recommended for patients with a definite mural nodule, MD features, or positive FNA cytologic findings on EUS, whereas the other patients are observed with surveillance. We then retrospectively compared the performance of the UCLA algorithm with the 2012 Guidelines algorithm 11 using our 103 patients who underwent surgery. According to the UCLA algorithm (Figure 2 ), all patients with malignant disease met criteria to undergo surgery. According to the 2012 Guidelines algorithm, 61 patients with malignant disease met one of the criteria to undergo surgery but 3 patients did not. For prognostication of malignant disease, the UCLA algorithm showed a sensitivity of 100%, specificity of 10%, PPV of 65%, NPV of 100%, and accuracy of 66%, whereas the 2012 Guidelines algorithm showed a sensitivity of 95%, specificity of 10%, PPV of 64%, NPV of 57%, and accuracy of 63%. this study was to perform a thorough analysis of our institution's extensive experience with resected MD or mixed IPMNs to determine whether 10.0 mm is an appropriate cutoff for MPD diameter as a high-risk feature for malignant disease.
Only a few studies have addressed the significance of an MPD diameter less than 10.0 mm in relation to the presence of malignant disease in IPMNs involving the MD. In their large cohort study of patients with MD or mixed IPMNs, Hackert et al 14 showed
that the rates of malignant disease of those who underwent resection with an MPD diameter of 5.0 to 9.9 mm and 10.0 mm or greater were 59% and 73%, respectively. These rates are consistent with those of the present study (53.7% and 67.7%, respectively) ( The present study demonstrated that an MPD diameter of 7.2 mm or greater was associated with the presence of malignant disease in patients with MD or mixed IPMNs. Twentythree patients had an MPD diameter of 7.2 to 9.9 mm; among them, malignant disease was identified in 20 (87%). Application of the 2012 Guidelines algorithm retrospectively to our study cohort identified 3 patients who did not meet any criteria for surgery by CT, MRI, or EUS but were eventually diagnosed with malignant disease in their surgical specimens.
Because of these missed cases, we propose a new modified management algorithm that includes lowering the MPD diameter cutoff to 7.2 mm (Figure 2) . Compared with the 2012 Guidelines algorithm, the UCLA algorithm has a higher sensitivity (100% vs 95%) and NPV (100% vs 57%) for identifying malignant IPMNs. However, these provisional statistics require confirmation with an independent validation cohort because they are based on the same data set used to determine our proposed algorithm. Sixty-two of 64 patients (97%) with malignant IPMNs had an MPD diameter of 7.2 mm or greater on CT or MRI. Two patients with malignant IPMNs and an MPD diameter less than 7.2 mm each met one of the criteria for surgery: one had a definite mural nodule on EUS findings, and the other was symptomatic with pancreatitis and also had a thickened MPD wall suggestive of involvement on EUS. Endoscopic ultrasonography played a key role in detecting possible malignant disease in these patients with an MPD diameter of 5.0 to 7.2 mm.
In addition to EUS, pancreatoscopy and intraductal ultrasonography can be used to help determine preoperatively whether the IPMN involves the MD by detecting the presence of papillary fronds. [17] [18] [19] Because of the technical difficulty and risk for pancreatitis, both techniques are often used selectively in equivocal cases of MD involvement in patients who are high-risk surgical candidates or who request a more certain diagnosis before their operation.
Limitations
Several limitations of the present study should be acknowledged. First, this retrospective, single-institutional study is limited by significant selection bias, and our proposed management algorithm ( Figure 2 ) will require validation in other patient cohorts.
Patients were selected for surgery after a multidisciplinary conference and an extensive discussion in the clinic that incorporated the 2012 Guidelines as one component of the decision. Median duration from the first consultation to surgery was 25 (range, 1-323) days. Although estimating the overall rate of malignant disease in patients with IPMNs involving the MD is difficult, we reviewed the medical records of all patients with pancreatic cystic disease discussed at our multidisciplinary conference who were treated nonoperatively. From November 1, 2012, to December 31, 2015 (the study period for which comprehensive multidisciplinary conference records were available), only 3 patients (8%) with an MPD diameter of 5.0 mm or greater were recommended for surveillance owing to their age, frailty, or significant medical comorbidities. For comparison, 34 patients underwent resection during that time. Thus, we conclude that our cutoff of an MPD diameter of 7.2 mm or greater was derived from most of the patients seen at UCLA with an MPD diameter of 5.0 mm or greater, and our study is likely to approximate the true cancer rate associated with this finding. The second limitation is that a detailed comparison of neoplastic involvement of the pancreatic ductal system (ie, MD, BD, or both) between preoperative radiologic examinations and pathologic evaluation was not performed for all patients. The pathologic information is not available in the preoperative setting when the decision to operate is being made. Third, preoperative serum carbohydrate antigen 19-9 levels, EUS findings, or FNA cytologic findings were evaluated for only 44 (42.7%), 80 (77.7%), or 61 (59.2%) of the 103 study patients, respectively. Serum carbohydrate antigen 19-9 levels and positive FNA cytologic findings have previously been shown to be correlated with malignant disease in patients with IPMN.
20,21 Fourth, we classified high-grade dysplasia and invasive adenocarcinoma as malignant disease. Although how frequently high-grade dysplasia would progress to invasive malignant disease is unclear, surgery is likely to be the most beneficial in patients with high-grade dysplasia before it has progressed to invasive adenocarcinoma, as stated by the recent American Gastroenterological Association Institute Guidelines. 22 The PPV for malignant disease using the UCLA algorithm was 65%, which was comparable to that of the 2012 Guidelines algorithm (64%). We believe that this PPV associated with the 7.2-mm MPD diameter cutoff yields an acceptable negative operative rate, considering a mortality impact of overlooking malignant disease and a very low operative mortality rate (<2%) at high-volume centers. 23 Last, in this study we did not
